The evolving translational potential of small extracellular vesicles in cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cancer extracellular vesicles (EVs) show promise as biomarkers and therapeutics. Understanding cancer-specific pathways governing EV biogenesis is crucial for improving cancer diagnosis, prognosis, and developing targeted therapies.
Area Of Science
- Oncology
- Biotechnology
- Molecular Biology
Background
- Cancer-derived extracellular vesicles (EVs), including small EVs (sEVs), play critical roles in cancer progression.
- These EVs contain unique biomolecular cargo (proteins, nucleic acids, lipids) with potential for biomarker discovery.
Purpose Of The Study
- To review progress in cancer sEV biomarker discovery and therapeutics.
- To identify knowledge gaps hindering the full potential of sEVs in cancer diagnostics and therapy.
Main Methods
- Literature review focusing on cancer sEVs.
- Analysis of current advancements in biomarker identification and therapeutic applications.
Main Results
- Significant progress has been made in identifying cancer biomarkers and developing sEV-based therapeutics.
- Identification of specific cargo has opened opportunities for cancer diagnosis and prognosis.
Conclusions
- A comprehensive understanding of cancer-specific EV biogenesis pathways is lacking.
- Addressing these knowledge gaps is essential for discriminating EV actions and developing targeted cancer therapies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...